A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced antico-agulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors.Blood - Crowther, M; Mathur, V; Kitt, M (2013)
Abstract 3636.